Cui M, Hu Y, Liao Q
Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Zhonghua Wai Ke Za Zhi. 2022 Jun 28;60(8):792-795. doi: 10.3760/cma.j.cn112139-20220111-00022.
Parathyroid carcinoma is a rare endocrine malignancy with an increasing rate of incidence. Most parathyroid carcinoma patients will develop local recurrence or metastases leading to poor prognosis. Medical management is the mainstay of treatment for patients with unresectable parathyroid carcinoma. However, the therapeutic outcome of medical management remains unsatisfactory restricted by limited options and efficacy. With the deepening of research, several novel drugs have been reported to be applied in the treatment of parathyroid carcinoma. Calcimimetics and receptor activator for nuclear factor-κB ligand inhibitors aiming to control hypercalcemia have been applied in the endocrine therapy of parathyroid carcinoma. Besides, preliminary studies have shown the therapeutic effects of targeted therapy and immunotherapy on parathyroid carcinoma. These new drugs have shed light on this clinical dilemma; however, their clinical efficacy remains to be determined. In this article, the recent progress in the medical management of parathyroid carcinoma is updated.
甲状旁腺癌是一种罕见的内分泌恶性肿瘤，发病率呈上升趋势。大多数甲状旁腺癌患者会发生局部复发或转移，导致预后不良。药物治疗是不可切除甲状旁腺癌患者的主要治疗手段。然而，受限于有限的选择和疗效，药物治疗的效果仍不尽人意。随着研究的深入，已有几种新型药物被报道可用于甲状旁腺癌的治疗。旨在控制高钙血症的拟钙剂和核因子κB受体活化剂配体抑制剂已应用于甲状旁腺癌的内分泌治疗。此外，初步研究显示了靶向治疗和免疫治疗对甲状旁腺癌的治疗效果。这些新药为这一临床困境带来了曙光；然而，它们的临床疗效仍有待确定。本文更新了甲状旁腺癌药物治疗的最新进展。
